Dan
The failure rate of stage 2 and 3 clinical trials due to poor efficacy is high - P3 is over 54%.
IMM phase 2b efficacy data is disappointing for sure. Thus far......wait for OS
Must admit I was lower than a snakes belly after announcement. It's a tough business.
Market cap smashed and retail holders (generalisation) run for the hills.
A New approved drug takes up to 10 years and average cost over $2 billion to get to market.
IMM is not PRR and the strategy is to develop multiple products and license out to big pharma
Objective- multiple income streams that fund development of novel immuno - oncology and autoimmune drugs
AND provide shareholders with a great return on investment- dividends.
Definitely a set-back with AIPAC trial but the real anomaly is the placebo arm not Efti that performed as expected.
Thomas Edison didn't give up after his first light bulb didn't work - that said Immutep do not have as many chances to prove Efti works.
TACTI-002 looking great.
Updated data soon if positive would help sentiment- if not positive, game over imo
- Forums
- ASX - By Stock
- IMM
- CYTLIMIC positive results - YNP01 Phase 1 trial
CYTLIMIC positive results - YNP01 Phase 1 trial, page-11
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $537.4M |
Open | High | Low | Value | Volume |
37.0¢ | 38.3¢ | 36.5¢ | $1.060M | 2.841M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 48648 | 36.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.0¢ | 13814 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 48648 | 0.365 |
7 | 164694 | 0.360 |
4 | 31498 | 0.355 |
7 | 161310 | 0.350 |
3 | 12221 | 0.345 |
Price($) | Vol. | No. |
---|---|---|
0.370 | 13814 | 2 |
0.375 | 175836 | 7 |
0.380 | 137322 | 5 |
0.385 | 53062 | 4 |
0.390 | 197301 | 5 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online